Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Receivables (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Change in Receivables for 16 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 52.78% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$408000.0 through Dec 2025, up 87.88% year-over-year, with the annual reading at -$408000.0 for FY2025, 87.88% up from the prior year.
  • Change in Receivables for Q4 2025 was $1.5 million at Anika Therapeutics, up from -$1.3 million in the prior quarter.
  • The five-year high for Change in Receivables was $6.2 million in Q2 2023, with the low at -$4.8 million in Q3 2024.
  • Average Change in Receivables over 5 years is $468850.0, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Change in Receivables skyrocketed 285.53% in 2021, then crashed 959.27% in 2023.
  • Over 5 years, Change in Receivables stood at -$2.1 million in 2021, then skyrocketed by 130.74% to $647000.0 in 2022, then soared by 70.63% to $1.1 million in 2023, then skyrocketed by 196.38% to $3.3 million in 2024, then crashed by 52.78% to $1.5 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $1.5 million, -$1.3 million, and $2.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.